Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients
Authors:
- Toni IbrahimToni Ibrahim
- Emanuele SacannaESEmanuele Sacanna
- Michele GaudioMGMichele Gaudio
- Laura MercataliLaura Mercatali
- Emanuela ScarpiESEmanuela Scarpi
- Wainer ZoliWZWainer Zoli
- Patrizia SerraPSPatrizia Serra
- Rossana RicciRRRossana Ricci
- Luigi SerraLSLuigi Serra
- Yibin KangYKYibin Kang
- Dino AmadoriDADino Amadori
- 1 December 2011
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 11 (6) , 369-375
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factorsCancer Letters, 2009
- Therapeutic implications of osteoprotegerinCancer Cell International, 2009
- RANKL signaling in bone physiology and cancerCurrent Opinion in Supportive & Palliative Care, 2007
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006
- Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric miceExperimental Hematology, 2006
- Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulationCancer, 2006
- Regulation of cancer cell migration and bone metastasis by RANKLNature, 2006
- Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasisNature Clinical Practice Oncology, 2006
- OPG, RANKL, and RANK in Cancer Metastasis: Expression and Regulation2004
- Metastasis to bone: causes, consequences and therapeutic opportunitiesNature Reviews Cancer, 2002